Balancing randomized trials with anecdote

Annals of Internal Medicine

Volumn 150, Issue 12, 2009, Pages 885-886

  Phillips, Paul S ^a  

^a SCRIPPS MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTIN; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; UBIDECARENONE;

CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; LIPID METABOLISM; MEDICAL LITERATURE; MYOPATHY; OUTPATIENT DEPARTMENT; PAIN; PHYSICIAN; PRIORITY JOURNAL; RHABDOMYOLYSIS; VITAMIN D DEFICIENCY;

EID: 67249100852     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-12-200906160-00014     Document Type: Editorial

References (23)

1. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281:1728-1734 [PMID: 10328074]
2. Cao P, Hanai JI, Tanksale P, Imamura S, Sukhatme VP, Lecker SH. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J. 2009. [PMID: 19406843]
3. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016 [PMID: 12814710]
4. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435 [PMID: 15755765]
5. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al; Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585 [PMID: 12353945]
6. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316 [PMID: 15337732]
7. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Asssociation; National Heart, Lung, and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572 [PMID: 12142128]
8. Linares LA, Golomb B, Jaojoco J, Sikand H, Phillips PS. The contemporary spectrum of rhabdomyolysis suggests its utility in assessing drug toxicity. Curr Drug Safety. 2009. [Forthcoming].
9. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858-868
10. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients. A randomized trial. Ann Intern Med. 2009;150:830-839
11. Molyneux S, Florkowski C, Lever M, George P. The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly [Letter]. N Z Med J. 2004;117:U1108. [PMID: 15477929] (Pubitemid 41519767)
12. Havranek JM, Wolfsen AR, Warnke GA, Phillips PS. Monotherapy with ezetimibe causing myopathy [Letter]. Am J Med. 2006;119:285-286 [PMID: 16490482] (Pubitemid 43255084)
13. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008;101:490-496 [PMID: 18312764] (Pubitemid 351199443)
14. Phillips PS. Ezetimibe and statin-associated myopathy [Letter]. Ann Intern Med. 2004;141:649. [PMID: 15492351]
15. Phillips PS, Ciaraldi TP, Kim DL, Verity MA, Wolfson T, Henry RR; Scripps Mercy Clinical Research Center. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids. Endocrine. 2009;35:38-46. [PMID: 19051066]
16. Durst R, Rund D, Schurr D, Eliav O, Ben-Yehuda D, Shpizen S, et al. One year experience with a low density lipoprotein apheresis system. Isr Med Assoc J. 2002;4:677-680 [PMID: 12440228] (Pubitemid 34987595)
17. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al; Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689-1693 [PMID: 18549841]
18. Becker DJ, Gordon RY, Morris PB, Yorko J, Gordon YJ, Li M, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83:758-764 [PMID: 18613992] (Pubitemid 351948689)
19. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7:133-139 [PMID: 11327519] (Pubitemid 32319321)
20. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74:1200-1201 [PMID: 12438974]
21. Rhabdomyolysis linked to Chinese red yeast rice. Prescrire Int. 2008;17:64. [PMID: 18516816]
22. Phillips PS, Haas RH. Observations from a statin myopathy clinic [Letter]. Arch Intern Med. 2006;166:1232-3; author reply 1233. [PMID: 16772252] (Pubitemid 43877635)
23. U.S. Food and Drug Administration. FDA warns consumers to avoid red yeast rice products promoted on internet as treatments for high cholesterol: products found to contain unauthorized drug [new release]. Rockville, MD: U.S. Food and Drug Administration; 2007. Accessed at www.fda.gov/bbs/topics/NEWS/2007/ NEW01678.html on 13 May 2009.